Latest News & Updates of Loncom Pharma

FDA updates nonclinical testing terminology, supporting broader use of scientifically valid NAMs in drug development while maintaining safety standards.

FDA’s latest 55 draft PSGs further clarify generic drug development, with continued focus on complex products and science-based BE approaches.

NMPA’s 2026 revised clinical trial inspection guidelines strengthen sponsor oversight, data governance, quality management, and risk-based compliance.

Loncom Pharma analyzes FDA ANDA bioequivalence updates and supports global generic drug development strategies.